These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 30066852)

  • 21. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
    Xu LJ; Ma Q; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
    Mol Med Rep; 2018 Jun; 17(6):8111-8120. PubMed ID: 29693186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process.
    Li F; Zhu T; Yue Y; Zhu X; Wang J; Liang L
    Oncol Rep; 2018 Aug; 40(2):775-782. PubMed ID: 29901173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 29. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
    Amarnath S; Mangus CW; Wang JC; Wei F; He A; Kapoor V; Foley JE; Massey PR; Felizardo TC; Riley JL; Levine BL; June CH; Medin JA; Fowler DH
    Sci Transl Med; 2011 Nov; 3(111):111ra120. PubMed ID: 22133721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pterostilbene Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors and Downregulation of Cell Survival Proteins in TRAIL-Resistance Triple Negative Breast Cancer Cells.
    Hung CM; Liu LC; Ho CT; Lin YC; Way TD
    J Agric Food Chem; 2017 Dec; 65(51):11179-11191. PubMed ID: 29164887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
    Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
    Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of exosomal PDL1 in tumour immune evasion.
    Daassi D; Mahoney KM; Freeman GJ
    Nat Rev Immunol; 2020 Apr; 20(4):209-215. PubMed ID: 31965064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
    Ansari RE; Craze ML; Althobiti M; Alfarsi L; Ellis IO; Rakha EA; Green AR
    Br J Cancer; 2020 Jan; 122(1):94-101. PubMed ID: 31819174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z; Jiang H; Zhu X; Liu X; Li J
    Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).
    Ma X; Wu J; Wang B; Liu C; Liu L; Sun C
    Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curcumin synergizes with resveratrol to inhibit colon cancer.
    Majumdar AP; Banerjee S; Nautiyal J; Patel BB; Patel V; Du J; Yu Y; Elliott AA; Levi E; Sarkar FH
    Nutr Cancer; 2009; 61(4):544-53. PubMed ID: 19838927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.